Useful markers to predict response to chemotherapy in patients with liver cancer

Difficult treatment Hepatocellular carcinoma is one of the cancers with the worst prognosis and more difficult treatment. Surgery is only possible when the tumor is well located and the protocol for liver transplantation requires specific requirements for number and size of tumor nodules. However, there is a drug used in advanced stages of hepatocellular carcinoma: … Continue reading “Useful markers to predict response to chemotherapy in patients with liver cancer”

Difficult treatment

Hepatocellular carcinoma is one of the cancers with the worst prognosis and more difficult treatment. Surgery is only possible when the tumor is well located and the protocol for liver transplantation requires specific requirements for number and size of tumor nodules.

However, there is a drug used in advanced stages of hepatocellular carcinoma: Sorafenib. It is a tyrosine kinase inhibitor which has an extremely specific action. As explained Isabel Fabregat “Sorafenib could act not only on tumor cells by inhibiting the growth and inducing cell death but also on cells accompanying the tumor, the stroma, by their ability to inhibit the formation of blood vessels to provide nutrients to the tumor cells. Sorafenib treatment induces a delay in tumor process but generally fails to produce the patient’s recovery. “

Therefore, many laboratories are currently working on the study of the action of this drug to improve therapy either attaching different drugs or selecting patients.

In this sense, the study of the research group in Biological Keys Invasive and Metastatic Phenotype led by Fabregat analyzed the phenotypic and molecular characteristics of several cell lines and in animal models and their response to Sorafenib.

Resistence biomarkers

“We have observed that the cells which exhibit a mesenchymal phenotype (where the tumor cells are less differentiated and are potentially more aggressive) and which express CD44, a marker of tumor-initiating cells, are resistant to Sorafenib.”

The study proposes CD44 as a potential marker that could be used clinically to select patients who will not respond to treatment and thus spare them the side effects.

Author: Joe Lovrek

Born in Houston, Raised in Trinity Texas

Leave a Reply